Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search


PharmaZen pre-tax profit jumps 134% for half year

August 1, 2019

Press Release

PharmaZen pre-tax profit jumps 134% to $1.83 million for the half year.

It has taken biotechnology company PharmaZen Limited just six months to surpass its record full year result of 2018.

Sales for the six months to June 30th jumped 50% to $8.312m from the prior year figure of $5.561m, and pre-tax profit increased 134% from $785,000 to $1.839m.

The full year 2018 result was a pre-tax profit of $1.792m on turnover of $12.573m.

Based in Christchurch, PharmaZen is an innovative developer, manufacturer and marketer of science-based, natural, nutritional ingredients. Shares in PharmaZen are traded through the Unlisted securities trading platform.

Managing Director Craig McIntosh described the result as being exceptionally pleasing.

“Our 2018 result gave shareholders a glimpse of the business’s potential as our long-term investments started to come on stream. The first six months of 2019 reinforces that performance but also starts to add some magnitude to the potential,” he said.

The full year pre-tax profit for the company was forecast at the company’s AGM to be $2.8m on turnover of $14.5m. McIntosh advised that the board of directors has signed off an upgraded full year forecast of $3.9m pre-tax profit on $16.5m turnover.

“While we to tend to err on the conservative side, the first six months have been well beyond expectations and it is an absolute credit to the staff and management that they have been able to accommodate such an increase.

“Not only has the company benefited from the strong demand, but it has also had a six-month run without any major disruption with capital projects.”

McIntosh believes this is a combination of timing and experience gained from prior projects but is quick to emphasis it doesn’t mean things are slowing down in terms of expansion.

“We have the resin column plant all on-site and ready for installation, and the building fitout for our finished product range is largely complete. The equipment for the facility will be arriving over the next two months and is going to enable us to produce a complete range of finished products – soft gel oils through to hard shell capsules.”

PharmaZen has also commenced design work for a 1200sqm building on their adjacent Nuttall Drive properties.

McIntosh was reluctant to divulge what the building would be housing but confirmed it would complete the full-site development.

“There are a couple of gaps left in our technology portfolio that we would like to have on the current site and we are looking to move our research and development department into a purpose-built facility. This will reinforce the site as our centre of excellence while at the same time allowing expansion in other geographically advantageous locations,” he said.

The management team has also been strengthened with the appointment of Katherine Reardon to head Sales and Marketing for consumer brands.

“Katherine comes to us with extensive industry background and is the ideal person to assist us launch our ranges domestically and internationally.”

The company is in the final stages of strengthening its product development function with further appointments.

© Scoop Media

Business Headlines | Sci-Tech Headlines


Ground Rules: Government Moves To Protect Best Growing Land

“Continuing to grow food in the volumes and quality we have come to expect depends on the availability of land and the quality of the soil. Once productive land is built on, we can’t use it for food production, which is why we need to act now.” More>>


Royal Society: Calls For Overhaul Of Gene-Technology Regulations

An expert panel considering the implications of new technologies that allow much more controlled and precise ‘editing’ of genes, has concluded it’s time for an overhaul of the regulations and that there’s an urgent need for wide discussion and debate about gene editing... More>>


Retail: Card Spending Dips In July

Seasonally-adjusted electronic card spending dipped in July by 0.1 percent after being flat in June, according to Stats NZ. Economists had expected a 0.5 percent lift, according to the median in a Bloomberg poll. More>>


Product Stewardship: Govt Takes More Action To Reduce Waste

The Government is proposing a new way to deal with environmentally harmful products before they become waste, including plastic packing and bottles, as part of a wider plan to reduce the amount of rubbish ending up in landfills. More>>


Earnings Update: Fonterra Sees Up To $675m Loss On Writedowns

“While the Co-op’s FY19 underlying earnings range is within the current guidance of 10-15 cents per share, when you take into consideration these likely write-downs, we expect to make a reported loss of $590-675 million this year, which is a 37 to 42 cent loss per share." More>>